The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

L. Poller, Wilbert S. Aronow, Dean G. Karalis, Krishnaswamy Chandrasekaran, Gary S. Mintz, Palle Petersen, Gudrun Boysen, John Godtfredsen, Daniel E. Singer, Robert A. Hughes, Daryl R. Gress, Mary A. Sheehan, Lynn B. Oertel, Sue Ward Maraventano, Dyan Ryan Blewett, Bernard Rosner, J. Philip Kistler, James H. Chesebro, Valentin Fuster, Jonathan L. Halperin

Research output: Contribution to journalLetterpeer-review

11 Scopus citations

Abstract

To the Editor: The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrates that treatment With “low dose” warfarin reduces strokes and mortality in patients with non-rheumatic atrial fibrillation.1 This report and the two other recent randomized studies, the Atrial Fibrillation, Aspirin, Anticoagulant Study (AFASAK) from Copenhagen2 and the North American Stroke Prevention in Atrial Fibrillation study (SPAF),3 agree on the benefits of administering warfarin for this condition. Vague terms such as “low dose” and “high dose” warfarin, used in the BAATAF study, must be challenged, however, when more precise means of quantifying the effect of warfarin are available. A.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalNew England Journal of Medicine
Volume325
Issue number2
DOIs
StatePublished - Jul 11 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation'. Together they form a unique fingerprint.

Cite this